Omidenepag isopropyl is a Small Molecule owned by Santen Pharmaceutical, and is involved in 17 clinical trials, of which 14 were completed, and 3 are ongoing.
DE-117 acts as an EP2 receptor agonist. DE-117 binds to EP2 receptor and maintains the aqueous humor outflow at significantly high level and reduces the intra-ocular pressure. EP2 receptors stimulate the adenylate cyclase. The subsequent raise in intracellular cAMP is responsible for the relaxing effect of this receptor on smooth muscle. Hence the pressure in eye is reduced.
The revenue for Omidenepag isopropyl is expected to reach a total of $2.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Omidenepag isopropyl NPV Report.
Omidenepag isopropyl Overview
Omidenepag isopropyl (DE-117, Eybelis, Omlonti) is a topical ocular hypotensive agent and an anti-glaucoma agent. It is formulated as drops for solution for ophthalmic route of administration. It is indicated for the treatment of open-angle glaucoma and ocular hypertension.
Santen Pharmaceutical Overview
Santen Pharmaceutical (Santen) focuses on the research, development, manufacturing and marketing of pharmaceutical products and medical devices. Its product portfolio includes prescription ophthalmic products for glaucoma, bacterial conjunctivitis, dry eye, inflammation, cataract, muscae volitantes, diabetic retinopathy, retinal detachment, hyposphagma, myopia, retinal detachment, amblyopia, astigmatism, strabismus, hordeolum, VDT syndrome and others; over-the-counter products ophthalmic products; anti-allergy ophthalmic products; and medical devices such as intraocular lenses (IOLs) and other ophthalmic products. Santen operates through its group companies located in Asia, Europe and the US. It operates production facilities in Noto, and Shiga, Japan; and Suzhou, China. Santen is headquartered in Kita-ku, Osaka, Japan.
The company reported revenues of (Yen) JPY266,257 million for the fiscal year ended March 2022 (FY2022), an increase of 6.7% over FY2021. In FY2022, the company’s operating margin was 14%, compared to an operating margin of 4.9% in FY2021. In FY2022, the company recorded a net margin of 10.2%, compared to a net margin of 3.7% in FY2021. The company reported revenues of JPY63,382 million for the second quarter ended September 2022, a decrease of 3.3% over the previous quarter.
Quick View – Omidenepag isopropyl
|Highest Development Stage|